ACADIA Pharmaceuticals Inc. vs Enbridge Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.06B), while Enbridge Inc trades at $51.67 (market cap $112.26B). The key difference: Enbridge Inc is far larger — about 22.2× ACADIA Pharmaceuticals Inc.'s market cap, and Enbridge Inc pays a 5.36% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | ENB | |
|---|---|---|
Market Cap | $5.06B | $112.26B |
Sector | Health | Energy |
52-Week High | $29.41 | $58.04 |
52-Week Low | $20.06 | $45.23 |
Enterprise Value | $4.18B | $196.07B |
Dividend Yield | — | 5.36% |
Trailing returns across standard periods
Latest headlines on both assets
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →